The obesity drug boom is attracting big bets from Big Pharma. Eli Lilly has inked a $1.3 billion deal with privately held Superluminal Medicines to discover next‑generation obesity drugs using artificial intelligence reuters.com. The partnership gives Lilly exclusive rights to develop and commercialise small‑molecule candidates identified by Superluminal’s AI platform targeting G‑protein‑coupled receptors (GPCRs), proteins that play key roles in metabolism, cell growth and immune responses reuters.com. The obesity market could be worth $150 billion within a decade, and Lilly already leads the field with its GLP‑1 drug Zepbound. This deal aims to fortify that dominance reuters.com.
Rival drugmakers such as Novo Nordisk are also racing to develop oral small‑molecule obesity pills and have cut multi‑billion‑dollar deals of their own reuters.com. Superluminal will receive upfront and milestone payments, equity investment and tiered royalties on future sales reuters.com. The start‑up is developing a separate lead candidate targeting melanocortin‑4 receptors for rare genetic obesity, slated to enter human trials next year reuters.com. The agreement highlights how AI‑enabled drug discovery is moving from hype to reality as pharmaceutical giants open their cheque books.
